Cargando…
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
During the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772042/ https://www.ncbi.nlm.nih.gov/pubmed/36568253 http://dx.doi.org/10.3389/fonc.2022.962947 |